In addition, to further confirm the anti-tumor progression and antimetastatic effects of WISP-1, rWISP-1 (12.5 and 25 μg/kg) was injected intratumorally three times a week into syngeneic mice starting 2 days after 344SQ cell injection (Fig. 10a). Here, CCN4 is linked to neoplasm.